FIBROBLAST GROWTH FACTOR (FGF) 21 AT MULTIMORBID CARDIOVASCULAR PATHOLOGY WITH ANXIETY AND DEPRESSIVE DISORDERS IN YOUNG AND MIDDLE-AGED MEN

Evaluate (FGF) 21 at multimorbid cardiovascular pathology (MCVP) (coronary artery disease (CAd), hypertension, metabolic syndrome (MS)) with non-psychotic mental disorders (NPMd) anxiety/ depressive type. Identify the effectiveness of visual-auditory effects in the treatment of these pathologies. design and methods: The study included 70 men (mean age 37,46±6,74) with MCVP divided into 4 groups by simple random sampling, and 20 healthy men (mean age 38,3±6,73 g). Patients in Group 1 (n = 22) received standard therapy CAd, hypertension and NPMd, in group 2 (n = 25) standard therapy CAd, hypertension, NPMd and visual-auditory correction. Patients of group 3 (n =23) received standard therapy CAd, hypertension, NPMd, visual-auditory correction and psychotherapy. used in the study: complex psychological test methods and laboratory-instrumental evaluation of the cardiovascular system. definition of FGF21 performed by ELISA using kits BCM diagnostics SK00145-01 (BCM diagnostics, uSA). Results: Identified a two-fold increase in the concentration of serum FGF 21 after the course of standard therapy in the first group. In the other groups showed a statistically significant decrease FGF21 after psychopharmacological and visual-auditory therapy. In all groups after treatment was observed significantly change the type of NdP «severe depression»,«clinical anxiety» to «mild depression»; «subclinical anxiety» (p <0,001). Conclusions: FGF21 may be important biomarker for early diagnosis of metabolic abnormalities in this pathology. Results indicate benefits of combined therapy MCVP with the use of psychotropic drugs and visual-auditory correction method. Choose the method of complex treatment given the side effects of pharmacological agents.

multimorbid cardiovascular pathology, fibroblast growth factor 21 (FGF21), anxiety and depressive disorders